OKYO Pharma Limited Statistics
Share Statistics
OKYO Pharma Limited has 33.89M shares outstanding. The number of shares has increased by 1.96% in one year.
| Shares Outstanding | 33.89M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 1.96% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 24.54M |
| Failed to Deliver (FTD) Shares | 28 |
| FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 272.00K, so 0.8% of the outstanding shares have been sold short.
| Short Interest | 272.00K |
| Short % of Shares Out | 0.8% |
| Short % of Float | 1.11% |
| Short Ratio (days to cover) | 2.83 |
Valuation Ratios
The PE ratio is -2563.69 and the forward PE ratio is null.
| PE Ratio | -2563.69 |
| Forward PE | null |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | -7.34 |
| P/FCF Ratio | -4.55 |
| PEG Ratio | n/a |
Enterprise Valuation
OKYO Pharma Limited has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 0.21, with a Debt / Equity ratio of 0.
| Current Ratio | 0.21 |
| Quick Ratio | 0.21 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -0.01 |
Financial Efficiency
Return on equity (ROE) is 0% and return on capital (ROIC) is 0.27%.
| Return on Equity (ROE) | 0% |
| Return on Assets (ROA) | -0.01% |
| Return on Capital (ROIC) | 0.27% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -2.10K |
| Employee Count | 8 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 22.42 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -39.43% in the last 52 weeks. The beta is -3.36, so OKYO Pharma Limited's price volatility has been lower than the market average.
| Beta | -3.36 |
| 52-Week Price Change | -39.43% |
| 50-Day Moving Average | 1.07 |
| 200-Day Moving Average | 1.24 |
| Relative Strength Index (RSI) | 50.21 |
| Average Volume (20 Days) | 56.08K |
Income Statement
In the last 12 months, OKYO Pharma Limited had revenue of $0 and earned -$16.83K in profits. Earnings per share was $0.
| Revenue | 0 |
| Gross Profit | -7.51K |
| Operating Income | -15.75K |
| Net Income | -16.83K |
| EBITDA | -15.75K |
| EBIT | - |
| Earnings Per Share (EPS) | 0 |
Balance Sheet
The company has $826.85K in cash and $0 in debt, giving a net cash position of $826.85K.
| Cash & Cash Equivalents | 826.85K |
| Total Debt | 0 |
| Net Cash | 826.85K |
| Retained Earnings | -142.52M |
| Total Assets | - |
| Working Capital | - |
Cash Flow
In the last 12 months, operating cash flow was -$9.49M and capital expenditures -$3, giving a free cash flow of -$9.49M.
| Operating Cash Flow | -9.49M |
| Capital Expenditures | -3 |
| Free Cash Flow | -9.49M |
| FCF Per Share | -0.32 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
OKYO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 0% |
| FCF Yield | -26.42% |
Analyst Forecast
The average price target for OKYO is $7, which is 560.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $7 |
| Price Target Difference | 560.4% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Scores
| Altman Z-Score | null |
| Piotroski F-Score | null |